Clinical Trial Update: Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine, to BoostrixTM and Inactivated Poliovirus Vaccine Administered Separately and With Revaxis® [Phase 3]

View source ↗

Summary

Phase 3 trial comparing GlaxoSmithKline's reduced antigen DTaP-IPV vaccine to Boostrix and standalone or Revaxis-administered IPV in tetanus, diphtheria, and pe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Pertussis
• Tetanus

Drugs mentioned

• Boostrix (Diphtheria, Tetanus, and Acellular Pertussis Vaccine)
• Inactivated Poliovirus Vaccine (Inactivated Poliovirus Vaccine)
• Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine (DTaP-IPV (reduced antigen))
• Revaxis (Diphtheria-Tetanus-Acellular Pertussis and Inactivated Poliovirus Vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Tetanus, Diphtheria | Phase 3 | Status: COMPLETED